Lexicon Pharmaceuticals, Inc. (LXRX) Stock Price & Analysis

Lexicon Pharmaceuticals, Inc. (LXRX) fell 0.89% to USD 2.24 as of September 8, 2026 at 09:37 UTC, according to Nexqual real-time market data.

LXRX last closed at USD 2.24; the session ranged USD 2.22–2.26 on volume of 1,044,611 shares. Market capitalization is —, with a 52-week range of USD 1.06–2.68 (NCM). Source: Nexqual, September 8, 2026 at 09:37 UTC.

Key Statistics (as of September 8, 2026 at 09:37 UTC)

Technical Analysis (LXRX)

Nexqual's technical model rates LXRX "STRONG SELL" based on 0 bullish and 5 bearish signals across 128 daily candles, as of September 8, 2026 at 09:37 UTC.

From Lexicon Pharmaceuticals, Inc.'s Latest SEC 10-K Filing (filed 2026-03-05)

Key Strengths & Strategy (as disclosed to the SEC)

• Food and Drug Administration, or FDA, issued complete response letters regarding our New Drug Application, or NDA, for ZYNQUISTA in type 1 diabetes in March 2019 and December 2024.
• We use "sotagliflozin" when referring to our development for HCM, "ZYNQUISTA" when referring to our development for type 1 diabetes and "INPEFA" when referring to our FDA-approved drug.
• The FDA has various programs, including Fast Track, priority review and accelerated approval, which are intended to expedite or simplify the process for developing and reviewing promising drugs, or to provide for the approval of a drug on the basis of a surrogate endpoint.
• We have received Fast Track designation from the FDA for development of pilavapadin in that indication and are currently advancing third party collaboration discussions for its further development and commercialization. • We have developed LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic disorders.

Partnerships

• We also seek to collaborate with other pharmaceutical and biotechnology companies, research institutes and academic institutions to capitalize on our drug target discoveries.   4 Novo Nordisk We entered into an exclusive license agreement with Novo Nordisk A/S in March 2025 under which we granted Novo Nordisk an exclusive, worldwide, royalty-bearing right and license to develop, manufacture and commercialize LX9851.
• Viatris We entered into an exclusive license agreement with Viatris Inc. in October 2024 under which we granted Viatris an exclusive, royalty-bearing right and license to develop and commercialize sotagliflozin in the licensed territory.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 09:37 UTC. This page is informational and not investment advice.